A systematic assessment of robustness in CNS safety pharmacology
The pronounced interlaboratory variability in Irwin datasets for the CNS-active compound MK-801 needs to be carefully considered when making decisions during drug development. While environmental and general study design had a minor impact, the study suggests that harmonisation of parameters and their scoring can limit variability and increase robustness.
Authors
- Eva‐Lotta von Rüden (ORCID: https://orcid.org/0000-0001-6864-5081)
- Ann‐Marie Waldron (ORCID: https://orcid.org/0000-0001-7788-6979)
- Johanna Kela
- U. Dressler
- Katharina Aulehner
- Kimberly Kerker
- Heidrun Potschka (ORCID: https://orcid.org/0000-0003-1506-0252)
- Heike Schauerte
- Alexander Pennington
- Martien J. Kas (ORCID: https://orcid.org/0000-0002-4471-8618)
- Steven Roger Talbot (ORCID: https://orcid.org/0000-0002-9062-4065)
- Helga Lorenz
- Washington Arias
- Helen Stirling (ORCID: https://orcid.org/0000-0002-9519-106X)
- Maria Reiber (ORCID: https://orcid.org/0000-0002-6132-723X)
- Sylvie Ramboz
- Isabel Seiffert
- Tarja Kuosmanen
- Christina L Torturo
- Tim P. Ahuis (ORCID: https://orcid.org/0000-0002-0853-730X)
- Sami M. M. Virtanen
Institutions
- Boehringer Ingelheim (Germany) (DE)
- University of Groningen (NL)
- Medizinische Hochschule Hannover (DE)
- Psychogenics (United States) (US)
- Orion Corporation (Finland) (FI)
- AbbVie (Germany) (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1111/bph.17358
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Deutsche Forschungsgemeinschaft